Extended indication Extension of indication to include in combination with pemetrexed and platinum chemotherapy the
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Pembrolizumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Oncology other
Extended indication Extension of indication to include in combination with pemetrexed and platinum chemotherapy the first -line treatment of adults and adolescents aged 12 years and older with unresectable advanced or metastatic malignant pleural mesothelioma.
Proprietary name Keytruda
Manufacturer MSD
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Infusion fluid
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Submission date February 2024
Expected Registration November 2024
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.